Surgery Websites
Thoracic Oncology Program »  Meet the Team »  Medical Oncologists »  Ross Okimoto, M.D.
Ross Okimoto, M.D.

Ross Okimoto, M.D.

Clinical Instructor

Contact Information

Orchid: Orchid 0000-0002-4467-8476
Open Popup

Creighton University School of Medicine 2009

  • Tufts Medical Center, Internal Medicine 2012
  • UCSF Medical Center, Medical Oncology 2014
  • American Board of Internal Medicine
  • American Board of Internal Medicine, Medical Oncology

Dr. Ross Okimoto is a medical oncologist specializing in the care of adult patients with soft tissue and bone sarcomas. He works with a team of surgeons, radiation oncologists and pathologists to provide the best possible outcomes for his patients.

Okimoto attended Creighton University School of Medicine. He completed his internal medicine residency training at Tufts Medical Center in Boston and his medical oncology fellowship at UCSF.

  Award  
  Confired By    
  Date    
  • Damon Runyon Clinical Investigator Award Finalist
  • 2021
  • National Cancer Institute R37 MERIT Award
  • 2021
  • American Society of Clinical Investigation Young Physician-Scientist Award
  • 2019
  • NIH-NCI Career Development Award (K08)
  • 2018
  • NIH-NCI Career Development Award (K08)
  • 2018 - 2023
  • UCSF DOM Cohort Iniative Award
  • 2018
  • A.P. Giannini Postdoctoral Fellowship
  • 2015
  • A physician-scientist, Okimoto conducts research in addition to providing clinical care. The overall goal of his laboratory-based investigations is to help improve outcomes for cancer patients. His current research work focuses on understanding the molecular mechanisms that promote tumor cell metastasis.

    Data provided by UCSF Profiles, powered by CTSI
    ORCID iD: 0000-0002-4467-8476 Additional info
    • Therapeutic degradation of Capicua (CIC) fused oncoproteins in undifferentiated sarcomas
      Sponsor:
      Sponsor ID:
      Funding Period:
      Jun 2021
      -
      May 2026
      Principal Investigator
    • Therapeutic rescue of the transcriptional repressor Capicua to inhibit lung cancer metastasis
      Sponsor:
      Sponsor ID:
      Funding Period:
      Feb 2018
      -
      Jan 2023
      Principal Investigator
    MOST RECENT PUBLICATIONS FROM A TOTAL OF 32
    Data provided by UCSF Profiles, powered by CTSI
    1. Quinn JJ, Jones MG, Okimoto RA, Nanjo S, Chan M, Yosef N, Bivona TG, Weissman JS. PMID: 3347912. Single-cell lineages reveal the rates, routes, and drivers of metastasis in cancer xenografts. Science. 2021. View in PubMed
    2. Quinn JJ, Jones MG, Okimoto RA, Nanjo S, Chan MM, Yosef N, Bivona TG, Weissman JS. Single-cell lineages reveal the rates, routes, and drivers of metastasis in cancer xenografts. Science. 2021 02 26; 371(6532). View in PubMed
    3. Nothdurft S, Thumser-Henner C, Breitenbücher F, Okimoto RA, Dorsch M, Opitz CA, Sadik A, Esser C, Hölzel M, Asthana S, Forster J, Beisser D, Kalmbach S, Grüner BM, Bivona TG, Schramm A, Schuler M. Functional screening identifies aryl hydrocarbon receptor as suppressor of lung cancer metastasis. Oncogenesis. 2020 Nov 19; 9(11):102. View in PubMed
    4. Kim JW, Ponce RK, Okimoto RA. Capicua in Human Cancer. Trends Cancer. 2021 01; 7(1):77-86. View in PubMed
    5. Lin YK, Wu W, Ponce RK, Kim JW, Okimoto RA. Negative MAPK-ERK regulation sustains CIC-DUX4 oncoprotein expression in undifferentiated sarcoma. Proc Natl Acad Sci U S A. 2020 08 25; 117(34):20776-20784. View in PubMed
    6. View All Publications

     

    Site Directory
      X